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Introduction
Zonisamide is a new drug with broad-spectrum antiepilepsy activity against partial as well as generalized seizures. The drug has been commercially licensed in Japan since 1989. Before licensure, randomized, controlled trials of zonisamide were *Corresponding author. Tel.: +81 22 717 7284; fax: +81 22 717 7290.
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performed by 4 authors; 1-4 3 studies were of treatment in adults, [1] [2] [3] and 1 study examined pediatric treatment. 4 The observation period of these studies was 12-16 weeks in adults, and 8 weeks in children. All studies were confined to zonisamide treatment of generalized seizures. Postmarketing research, performed at 25 institutions over a 5-year period, investigated the clinical effectiveness and safety of zonisamide for the treatment of childhood epilepsy. The purpose of this postmarketing study was to compare the long-term efficacy of zonisamide in the treatment of epilepsy in intellectually nor-mal children to that in intellectually disabled children.
Methods

Patients and study design
A total of 759 patients were included in the study.
All were under 15 years of age. Ages of patients distributed as follows: less than 1 year, 20 patients (3%); 1-5 years, 213 patients (28%); 6-10 years, 282 patients (37%); and 11-15 years, 244 patients (32%). Of the study subjects, 418 were evaluated as intellectually normal, and 341 were intellectually disabled, with scores less than 50 based on their intelligent quotient (IQ) or development quotient (DQ). The IQ was evaluated by Tanaka-Binet method (Japanese edition of the Stanford-Binet Intelligence Scale), and in a few cases, by Wechsler Intelligence Scale for Children--Revised. The DQ was evaluated by the Tsumori-Inage method and Enjoji method (both are evaluated by interviewing parents, similar to the Denver Developmental Screening Test). The observation period of the study was between 6 months and 5 years. Overall improvement in seizure control was evaluated in both the intellectually normal and the intellectually disabled groups. In the intellectually normal group, approximately 15% of patients had temporal lobe epilepsy and approximately 55% had non-temporal lobe epilepsy. Generalized epilepsies were found in less than 20% of this group. In contrast, in intellectually disabled patients, approximately 7% had temporal lobe epilepsy and 35% non-temporal lobe epilepsy. Generalized epilepsy was found in almost one-half of this study group's subjects.
A total of 729 patients out of the initial 759 patients were included in the final evaluation. Thirty patients were eliminated from analysis because of loss to follow-up due to adverse effects, change of address, too few seizures to evaluate, or other reasons. Of the intellectually normal group, 401 patients completed the study; of the intellectually disabled group, 328 completed the study (Table 1) . Thirty patients were excluded because of interruption of follow-up by adverse effects, changes of address, etc. 
Evaluation of safety and efficacy
The efficacy of zonisamide in the treatment of seizures was evaluated on the basis of improvement over a minimum 5-month period of observation following the initiation of treatment. Patients who were observed less than 5 months were not included in the efficacy analysis. Statistical analysis was performed using the chi-square method. Doses of zonisamide varied from 2 mg/kg per day to more than 10 mg/kg per day, and about 70% of patients received 2-8 mg/kg per day of zonisamide. Zonisamide was regarded as effective for seizure control if the seizure frequency was reduced by ≥50% compared to baseline seizure frequency measured before treatment began. The improvement rate was defined as the percentage of the total number of patients meeting this efficacy standard. Adverse effects were recorded for all patients.
Sixty-one percent of the patients in the intellectually normal group were treated with zonisamide monotherapy (Table 2) . Twenty-eight percent of the patients were treated with zonisamide and 1 other antiepilepsy drug. In contrast, zonisamide monotherapy was given to only 14% of the patients in the intellectually disabled group. Zonisamide was given together with 2 other antiepilepsy drugs in 39% of this group's patients. The mean number of AEDs, including zonisamide, was 1.61 in the intellectually normal group and 2.94 in the intellectually disabled group.
Results
Efficacy
The overall improvement rating for generalized seizures is shown in Table 3 . The characteristics of the seizures were different for the 2 groups. Generally speaking, improvement was significantly beneficial for persons of normal intelligence (80%, P < 0.001), notably for tonic (89%, P < 0.001), and generalized tonic-clonic seizures (87%, P < 0.01), as well as other seizure types (80%, P < 0.05). For all categories of partial seizures, the improvement 92/204 (45%) * P < 0.05, * * P < 0.01, * * * P < 0.001 between the intellectually normal and the intellectually disabled groups, respectively; GTC = generalized tonicclonic. rating was significantly higher (P < 0.001) in the intellectually normal group (86%) than in the intellectually disabled group (64%) ( Table 4) . Table 5 compares the improvement rating according to the classification of epilepsy syndromes. The improvement rating was higher (P < 0.001) in the intellectually normal group (78%) than in the intellectually disabled group (43%). In the intellectually disabled group, patients with partial epilepsy showed a slightly better response than those with generalized epilepsy (50% versus 36%, P < 0.01). Table 6 shows the improvement rating for patients with various types of generalized epilepsies. Primary generalized epilepsy was better controlled by zonisamide (P < 0.001) in intellectually normal patients (91%) than in intellectually disabled patients (58%). The improvement rating data for partial epilepsies is shown in Table 7 . Only temporal lobe epilepsy did not show a significant difference in the improvement rating between the 2 groups. Table 8 shows the relationship between improvement rates and age of epilepsy onset. In any age group, the improvement rating was greater (P < 0.001) in the intellectually normal group (78%) than in the intellectually disabled group (43%). 
Safety
Adverse effects were experienced by 21% of the intellectually normal patients, and by 28% of the intellectually disabled patients (see Table 9 ). The incidence of adverse events was slightly higher in the intellectually disabled group, but there is no significant difference between these groups. In total, 24% of the 759 patients in this study experienced some adverse effects.
In Table 10 , a comparison of adverse events observed with zonisamide monotherapy (16%) versus combined therapy (28%) demonstrates that fewer adverse effects were observed in the monotherapy group (P < 0.001). There were no significant differences in adverse events between age groups, except that in the combined therapy group of patients under 1 year of age, the incidence of adverse effects was increased (50%).
Discussion and conclusions
Before the commercial licensing of zonisamide in Japan, a placebo-controlled study in children showed that the percentage of patients with a 50% or higher decrease in seizure frequency was 50.0% and 43.8%, by zonisamide and valproate, respectively. 4 This study was done by 8 weeks of observation. Our study of long-term observation showed that the overall improvement rate was 62%, which was slightly higher than the placebocontrolled study results. The patients evaluated before launch had more frequent seizures--more than 4 times a month. After commercial licensing, zonisamide was also administered to many patients having infrequent seizures. The difference of the efficacy of zonisamide before and after the licensure is likely due to the background seizure frequency of the patients. In intellectually normal children, the overall improvement rate was thought to be quite high (78%); furthermore, patients with generalized epilepsy in the intellectually normal group showed 82% improvement.
It has generally been thought that zonisamide is more efficacious for partial epilepsy than generalized epilepsy. 5 It was reported that patients who had some temporal lobe abnormalities verified by EEG, computed tomography, or positron emission tomography responded well to zonisamide. 6 In that report, zonisamide was effective for partial epilepsy as well as generalized epilepsy with temporal lobe lesions. In the present study, however, zonisamide demonstrates efficacy for generalized epilepsy equal to or greater than its efficacy for partial epilepsy. The patients with generalized epilepsy who responded well to zonisamide might have had some temporal lobe abnormalities.
In comparing the efficacy of zonisamide for intellectually normal and disabled patients, zonisamide was more effective for intellectually normal patients. In general, intellectually disabled children have various kinds of central nervous system disturbances. These disturbances relate to the severity of seizures in epileptic patients with intellectual disability. However, even for intellectually disabled patients, zonisamide had good efficacy for seizure control. Zonisamide can be recommended for the treatment of both partial and generalized seizures in intellectually disabled children with epilepsy.
Treatment-emergent adverse effects were observed to have almost the same incidence in the normal intelligence and the intellectually disabled groups. Zonisamide monotherapy demonstrated less frequent adverse effects than zonisamide combined therapy. Combined antiepilepsy therapy often induces adverse effects more frequently in any antiepilepsy drug, not only zonisamide. 7 In the treatment of epileptic children with zonisamide, anhidrosis accompanied by elevated body temperature has been reported, especially during summer. 8, 9 Moreover, Shimizu et al. reported a case of an intellectually disabled 2-year-old boy demonstrating a heat stroke-like episode associated with zonisamide treatment. 10 This patient showed hyperpyrexia and oligohidrosis. In the present study, cases with anhidrosis were not reported by the doctors. However, anhidrosis or oligohidrosis is often difficult to observe, especially by intellectually disabled patients. Hyperpyrexia and oligohidrosis should be carefully monitored during zonisamide treatment.
